Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

PCD Logo

CME ACTIVITY

Continuation With Statin Therapy and the Risk of Primary Cancer: A Population-Based Study

Cases of Cancer Hazard Ratio (95% Confidence Interval)
Women (n = 4,095) 1 (0.99–1.01)
Men (n = 4,567) 0.98 (0.97–0.99)
Age 21–49 y (n = 696) 0.99 (0.97–1.02
Age 50–65 y (n = 4,164) 0.98 (0.97–0.99)
Age ≥66 (n = 3,802) 0.98 (0.97–0.99)
Low statin efficacy (n = 3,712) 0.99 (0.98–1.01)
Medium statin efficacy (n = 4,267) 0.99 (0.98–1.01)
High statin efficacy (n = 583) 0.95 (0.92–0.97)

Figure 1. Proportional effects of persistence with statin therapy on reduction of risk for overall cancer per 10% of follow-up days covered with statins. Squares indicate adjusted hazard ratios for all covariates listed in Table 2. Horizontal lines indicate 95% confidence intervals. The 3 statin efficacy levels were created on the basis of expected amounts of low-density lipoprotein reduction from baseline.

Return to article



The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.

 
For Questions About This Article Contact pcdeditor@cdc.gov
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #